miR‑888 regulates cancer progression by targeting multiple targets in lung adenocarcinoma

miR-888 通过靶向肺腺癌中的多个靶点来调节癌症进展

阅读:6
作者:Ji-Xiang Cao

Abstract

Aberrantly expressed miRNAs play a crucial role in the progression of lung adenocarcinoma. However, to date, the role of miR‑888 in lung adenocarcinoma progression is unclear. In the present study, the biological function of miR‑888 and its underlying mechanism in lung adenocarcinoma progression were explored. RT‑qPCR was performed to detect the expression of miR‑888 in 38 matched lung adenocarcinoma samples respectively. Next, the effects of miR‑888 on the proliferation, invasion and migration of lung adenocarcinoma A549 cells were evaluated by a series of gain‑ and loss‑of‑function assays. Our results revealed that miR‑888 was significantly upregulated in lung adenocarcinoma tissues, and its expression was markedly associated with clinical staging in patients. Moreover, ectopic expression of miR‑888 in vitro was revealed to function as a double‑edged sword in the progression of lung adenocarcinoma A549 cells by targeting multiple targets. Overexpression of miR‑888 promoted the invasion and migration of lung adenocarcinoma A549 cells by targeting E‑cadherin and tissue inhibitor of metalloproteinase 2. In addition, ectopic expression of miR‑888 inhibited the proliferation of lung adenocarcinoma A549 cells by targeting cell division cycle 7 (CDC7). In addition, the immunohistochemical results and The Cancer Genome Atlas (TCGA) database revealed that CDC7 was significantly upregulated in lung adenocarcinoma tissues, suggesting that miR‑888 may function as an oncogene in the progression of lung adenocarcinoma patients, and the miR‑888/CDC7 axis was not the dominant pathway for CDC7 regulation in patients with lung adenocarcinoma. In conclusion, our findings indicated that miR‑888 may act as a potential new therapeutic target for patients with lung adenocarcinoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。